Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Quarterly Dividend of $0.82

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Thursday, October 29th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share by the biopharmaceutical company on Wednesday, December 30th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, December 15th.

Gilead Sciences has a dividend payout ratio of 38.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Gilead Sciences to earn $9.94 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.0%.

Gilead Sciences Stock Performance

Shares of GILD opened at $165.61 on Friday. Gilead Sciences has a 12 month low of $114.02 and a 12 month high of $165.70. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market cap of $205.35 billion, a PE ratio of -62.03 and a beta of 0.31. The stock has a fifty day moving average price of $150.33 and a 200-day moving average price of $139.55.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.47 earnings per share. Equities research analysts predict that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GILD has been the topic of a number of analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a research report on Friday. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $162.00.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.